| |
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now. 
|
|
Today’s Big NewsJan 30, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By Nick Paul Taylor Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. |
|
|
|
By Nick Paul Taylor Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its clinical data package. |
By Nick Paul Taylor Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, Principia Biopharma and Synthorx. |
Sponsored by Salesforce Drug development and commercialization leads to tremendous advances in medicine and improvements to everyday life, but it often comes at a cost. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By James Waldron Cargo Therapeutics is lightening its load, jettisoning 50% of its employees along with the CAR-T company’s lead candidate in the wake of weak durability and serious side effects. |
By Ben Adams Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes. |
By James Waldron Shionogi’s respiratory syncytial virus antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. |
By Kevin Dunleavy Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June 2026 after leading Japan’s largest drugmaker for 11 years. |
By Darren Incorvaia Pregnancy comes with unique health risks and considerations, but pregnant people also continue to experience the same health problems that nonpregnant people do. Despite this, a new study has found that fewer than 1% of randomized controlled trials in the U.S. include pregnant participants. |
By Darren Incorvaia Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in patients with amyotrophic lateral sclerosis. Now, a new study has not only confirmed that sleep disruption is a symptom of ALS but has identified two potential hormone therapies that could treat it. |
By Zoey Becker During the hearing, Senate Finance Committee members lobbied a flurry of largely vaccine-related questions at the HHS nominee. |
By Kevin Dunleavy For "ethical" reasons, Merck has halted the phase 3 HYPERION trial of its pulmonary arterial hypertension (PAH) treatment Winrevair after reviewing positive interim results from another study and evaluating the drug’s overall clinical program. All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said. |
By Fraiser Kansteiner Despite finishing strong in 2024, Teva’s cautious approach to the new year appears to have investors spooked. The company's subdued guidance likely explains the performance of Teva’s stock, which plunged 13% on Wednesday. |
Fierce podcasts Don’t miss an episode |
| While major payers skipped out on this year’s event, health tech companies, health systems and insurtechs all made appearances to share their latest updates with investors. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
